RA Capital Management 13F holdings, Q1 2011
Holdings as of March 31, 2011 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 21 US equity positions worth $129.6m in its Q1 2011 13F filing. The largest position was SEQUENOM INC at 12.0% of the reported book, followed by PHARMASSET INC and VALEANT PHARMACEUTICALS INTL. Against the Q4 2010 filing, it opened 11 new positions, added to 2 and reduced 5 among the top 21 holdings.
What did RA Capital Management own in Q1 2011? Top 21 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2010 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 12.0% | $15.6m | 2,462,879 | 89% | added | |
| 2 | PHARMASSET INC | 9.0% | $11.6m | 147,761 | -20% | reduced | |
| 3 | VALEANT PHARMACEUTICALS INTL | 8.1% | $10.5m | 211,500 | 0% | held | |
| 4 | ALXN ALEXION PHARMACEUTICALS INC | 7.7% | $10.0m | 101,050 | 0% | held | |
| 5 | AFFYMAX INC | 7.6% | $9.8m | 1,671,908 | – | new | |
| 6 | ARTHROCARE CORP | 7.5% | $9.7m | 290,319 | -21% | reduced | |
| 7 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 6.5% | $8.4m | 5,173,708 | – | new |
| 8 | GILD GILEAD SCIENCES INC | Healthcare | 6.2% | $8.1m | 190,000 | – | new |
| 9 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 5.3% | $6.9m | 103,050 | 0% | held |
| 10 | JAZZ PHARMACEUTICALS INC | 5.3% | $6.9m | 215,424 | -49% | reduced | |
| 11 | DYNAVAX TECHNOLOGIES CORP | 4.7% | $6.0m | 2,191,071 | -34% | reduced | |
| 12 | BSTC BIOSPECIFICS TECHNOLOGIES CO | 4.6% | $6.0m | 234,362 | -22% | reduced | |
| 13 | ADVENTRX PHARMACEUTICALS INC | 3.8% | $5.0m | 2,365,000 | – | new | |
| 14 | COLUMBIA LABS INC | 3.1% | $4.1m | 1,076,116 | 5% | added | |
| 15 | RGEN REPLIGEN CORP | Healthcare | 2.6% | $3.3m | 889,741 | – | new |
| 16 | TENGION INC | 2.0% | $2.6m | 1,060,070 | – | new | |
| 17 | ENDOCYTE INC | 1.6% | $2.0m | 239,100 | – | new | |
| 18 | MAXYGEN INC | 0.7% | $926.0k | 178,015 | – | new | |
| 19 | ONCOTHYREON INC | 0.7% | $916.0k | 236,739 | – | new | |
| 20 | ENZB ENZO BIOCHEM INC | 0.6% | $787.0k | 187,900 | – | new | |
| 21 | DERMA SCIENCES INC | 0.3% | $436.0k | 44,940 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.